关注
Sarah Dyball
Sarah Dyball
在 Manchester.ac.uk 的电子邮件经过验证
标题
引用次数
引用次数
年份
Effectiveness and tolerability of benepali in rheumatoid arthritis patients switched from enbrel
S Dyball, V Hoskins, S Christy-Kilner, S Haque
ARTHRITIS & RHEUMATOLOGY 69, 2017
192017
Predicting progression from undifferentiated connective tissue disease to definite connective tissue disease: a systematic review and meta-analysis
S Dyball, M Rodziewicz, C Mendoza-Pinto, IN Bruce, B Parker
Autoimmunity Reviews 21 (11), 103184, 2022
122022
Lupus clinical trial eligibility in a real-world setting: results from the British Isles Lupus Assessment Group-Biologics Register (BILAG-BR)
S Dyball, S Collinson, E Sutton, EM McCarthy, IN Bruce, B Parker
Lupus Science & Medicine 8 (1), e000513, 2021
102021
Early infection risk in patients with systemic lupus erythematosus treated with rituximab or belimumab from the British Isles Lupus Assessment Group Biologics Register (BILAG …
M Rodziewicz, S Dyball, M Lunt, S McDonald, E Sutton, B Parker, ...
The Lancet Rheumatology 5 (5), e284-e292, 2023
92023
Acute paraquat exposure impairs colonic motility by selectively attenuating nitrergic signalling in the mouse
L Diss, S Dyball, T Ghela, J Golding, R Morris, S Robinson, R Tucker, ...
Autonomic Neuroscience 195, 8-15, 2016
72016
Determinants of health-related quality of life across the spectrum of connective tissue diseases using latent profile analysis: results from the LEAP cohort
S Dyball, JA Reynolds, AL Herrick, S Haque, H Chinoy, E Bruce, S Naz, ...
Rheumatology 62 (8), 2673-2682, 2023
42023
PROFILING RHEUMATOID ARTHRITIS BIOSIMILAR SWITCHERS: DATAFROM THE BRITISH SOCIETY FOR RHEUMATOLOGY BIOLOGICS REGISTER FOR RHEUMATOID ARTHRITIS
D De Cock, S Dyball, L Kearsley-Fleet, K Watson, K Hyrich
Rheumatology 57, 2018
42018
Predictors and prognostic factors influencing outcomes of anti-CD20 monoclonal antibodies in systemic lupus erythematosus: A systematic review update
M Rodziewicz, C Mendoza-Pinto, S Dyball, P Munguía-Realpozo, ...
Seminars in Arthritis and Rheumatism 65, 152346, 2024
32024
PS8: 154 Therapeutic and cardiovascular disease burden in undifferentiated connective tissue disease and systemic lupus erythematosus: results from the lupus extended …
S Dyball, J Reynolds, IN Bruce, B Parker
Lupus Science & Medicine 5 (Suppl 1), 2018
32018
Ianalumab in Sjögren's syndrome: what can we learn from lupus trials?
S Dyball, B Parker, IN Bruce
The Lancet 400 (10355), 807-808, 2022
22022
231 Pre-treatment anxiety and depression levels are correlated with less improvement in self-reported disease activity in rheumatoid arthritis patients treated with biological …
S Dyball, L Cordingley, JD Isaacs, G Wilson, A Morgan, K Hyrich, D Plant, ...
Rheumatology 57 (suppl_3), key075. 455, 2018
22018
An imperfect world: assessing safety of biological treatments in systemic lupus erythematosus. Comment on the article by Materne et al
M Rodziewicz, S Dyball, S Achieng, SR Brix, B Parker, IN Bruce
Arthritis & Rheumatology 76 (2), 315-316, 2024
12024
OP0013 APPLYING STANDARD CLASSIFICATION CRITERIA EXCLUDES UP TO A HALF OF ALL PATIENTS FROM CONNECTIVE TISSUE DISEASES (CTD) CLINICAL TRIALS
S Dyball, M Rodziewicz, AV Madenidou, J Reynolds, A Herrick, S Haque, ...
Annals of the Rheumatic Diseases 82 (Suppl 1), 9-9, 2023
12023
241 Profiling rheumatoid arthritis biosimilar switchers: datafrom the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
D De Cock, S Dyball, L Kearsley-Fleet, K Watson, K Hyrich, ...
Rheumatology 57 (suppl_3), key075. 465, 2018
12018
Added IMPACT: The first successful natural birth using certolizumab in obstetric APS
AV Madenidou, H Kither, S Dyball, IN Bruce, C Tower
Thrombosis research 241, 109088, 2024
2024
POS1320 FUNCTIONAL MAPPING OF AUTOIMMUNE PATIENTS BASED ON SERUM IMMUNE COMPLEXES REVEALS A COMMON TLR7/8 ENDOTYPE
S Hawtin, S Dyball, C André, S Appenzeller, B Bannert, H Brunner, ...
Annals of the Rheumatic Diseases 83 (Suppl 1), 1124-1124, 2024
2024
OP0149 DISCORDANCE IN CLINICAL RESPONSE AND PATIENT-REPORTED OUTCOMES IN MODERATE-SEVERE SLE: RESULTS FROM THE BRITISH ISLES LUPUS ASSESSMENT GROUP-BIOLOGICS REGISTER (BILAG-BR)
S Dyball, M Rodziewicz, E Sutton, B Parker, IN Bruce
Annals of the Rheumatic Diseases 83 (Suppl 1), 158-159, 2024
2024
POS0537 GLOBAL PERSPECTIVES ON GLUCOCORTICOID MANAGEMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM THE LUPHPOS SURVEY
S Dyball, CS Santos, KA Chandwar, E Chessa, M Mosca
Annals of the Rheumatic Diseases 83 (Suppl 1), 951-951, 2024
2024
OP0043 THE EFFECTIVENESS OF RITUXIMAB IN THE REAL-WORLD TREATMENT OF NEUROPSYCHIATRIC SLE: RESULTS FROM THE BRITISH ILES LUPUS ASSESSMENT GROUP BIOLOGICS REGISTER (BILAG-BR)
M Rodziewicz, S Dyball, T David, E Sutton, B Parker, IN Bruce
Annals of the Rheumatic Diseases 83 (Suppl 1), 137-138, 2024
2024
Clinical trial eligibility of a real-world connective tissue disease cohort: results from the LEAP cohort
S Dyball, AV Madenidou, M Rodziewicz, JA Reynolds, AL Herrick, ...
Seminars in arthritis and rheumatism, 152463, 2024
2024
系统目前无法执行此操作,请稍后再试。
文章 1–20